{
    "Trade/Device Name(s)": [
        "QUANTA Flash\u2122 B2GP1 IgA",
        "QUANTA Flash\u2122 aCL IgA",
        "QUANTA Flash\u2122M \u03b22GPI IgA Controls",
        "QUANTA Flash\u2122 aCL IgA Controls"
    ],
    "Submitter Information": "INOVA DIAGNOSTICS, INC.",
    "510(k) Number": "K120817",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MID",
        "MSV",
        "JJX"
    ],
    "Summary Letter Date": "October 31, 2013",
    "Summary Letter Received Date": "February 21, 2013",
    "Submission Date": "February 20, 2013",
    "Regulation Number(s)": [
        "21 CFR 866.5660"
    ],
    "Regulation Name(s)": [
        "Multiple autoantibodies immunological test system"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "anti-cardiolipin (aCL) IgA antibodies",
        "anti-\u03b22 glycoprotein-1 (\u03b22GP1) IgA antibodies"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "BIO-FLASH\u00ae instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay"
    ],
    "Methodologies": [
        "Semi-quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for QUANTA Flash aCL IgA and \u03b22GP1 IgA chemiluminescent immunoassays and controls for measurement of autoimmune antibodies related to antiphospholipid syndrome.",
    "Indications for Use Summary": "Aids in diagnosis of thrombotic disorders related to primary and secondary antiphospholipid syndrome by measuring anti-cardiolipin IgA and anti-\u03b22 glycoprotein-1 IgA antibodies in human plasma and serum, when used with other laboratory and clinical findings.",
    "fda_folder": "Immunology"
}